
-
Kinnate Biopharma NASDAQ:KNTE Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.
Location: | Website: www.kinnate.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
2.05%
Insider Ownership
0.16%
Institutional Own.
82.58%
Qtr Updated
03/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KIN-7136 (MEK inhibitor) +/- exarafenib Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1 Update | |
Phase 1 Update | ||
Exarafenib (KN-2787) +/- binimetinib Details Cancer, Solid tumor/s, Melanoma | Phase 1 Update |